Posted by Michael Wonder on 15 Dec 2022
Thea Pharma announces FDA approval of Iyuzeh for the reduction of elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension
15 December 2022 - Iyuzeh (latanoprost ophthalmic solution) 0.005% is the first and only preservative free formulation of latanoprost, the most prescribed prostaglandin F2α analogue in the United States.
Thea Pharma today announces US FDA approval for the new drug application of Iyuzeh (latanoprost ophthalmic solution) 0.005% for the reduction of elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.
